The Cancer Letter

Inside information on cancer research and drug development

Vol.
45
No.
35
September 20, 2019Sep 20, 2019
DOWNLOAD THE PDF
Herceptin: What it took to make it happen
Cover Story
Guest Editorial

Herceptin: What it took to make it happen

By Robert Bazell
One day in 1996, in my role as chief science correspondent for NBC News, I was rummaging through the usual huge (pre-internet) pile of press releases on my desk and zeroed in on one: a phase III trial of a treatment for an aggressive type of breast cancer that was desperate to accrue volunteers.
In a globe-spanning action, FDA and regulators in Australia, Canada jointly approve endometrial carcinoma therapy
Conversation with The Cancer LetterFree
By Paul Goldberg
FDA begins technology overhaul in preparation for tsunami of data and real-world evidence
By Matthew Bin Han Ong
Senate committee recommends $3 billion increase for NIH funding
By Alexandria Carolan
Fred Hutch's Gilliland to step down in 2020 as part of what he sees as generational change
Conversation with The Cancer Letter
By Paul Goldberg
Challenges to leveraging real-world evidence for FDA approval
Clinical
By Ash Malik

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account